United States Patent 5,753,627: Scope, Claim Construction, Expiration, and Somatostatin Receptor Imaging Patent Landscape

U.S. Patent No. 5,753,627 protected methods for detecting somatostatin-receptor-positive tumors and metastases using somatostatin peptides linked at the N-terminus to chelators carrying detectable metals or radionuclides. The claims reached radiolabeled peptide imaging, including peptide-chelator complexes using indium-111 and yttrium-90. The patent issued May 19, 1998, and its enforceable term expired in 2015 under the pre-1995 U.S. patent-term rules applicable to the family. It does not create a current U.S. barrier to generic or competing somatostatin-receptor radiopharmaceuticals. Later patents covering specific peptide sequences, radionuclide complexes, formulations, manufacturing processes, and products such as Lutathera and Netspot require separate analysis.

What invention does U.S. Patent 5,753,627 cover?

The patent covers an in vivo detection method with four central elements:

A subject has somatostatin-receptor-positive tumors or metastases.
A somatostatin peptide is administered.
A physiologically acceptable chelating group is linked directly or indirectly to the peptide's N-terminal amino group.
The chelator is complexed with a detectable element, and localization of the targeted receptors is recorded.

The invention is therefore a method-of-use patent directed to receptor-targeted imaging rather than a single pharmaceutical composition.

The broadest independent claim, claim 1, covers somatostatin peptides bearing an N-terminal chelator and complexed with one of four classes of detectable materials:

Detectable material under claim 1	Potential use
Gamma-emitting radionuclide	Nuclear scintigraphy or SPECT
Positron-emitting radionuclide	PET
Fluorescent metal ion	Optical or fluorescence-based detection
Paramagnetic ion	MRI or related imaging

The claim does not require a particular somatostatin analog, chelator, radionuclide, imaging instrument, tumor type beyond somatostatin-receptor positivity, or administration route.

How should claim 1 be construed?

Claim 1 has broad functional and structural reach, but it is limited by the required N-terminal attachment and receptor-localization step.

N-terminal chelator attachment

The chelator must be covalently linked to the N-terminal amino group of the somatostatin peptide. The linkage can be:

Direct;
Indirect through a spacer or bridging group;
An amide bond; or
A thiourea bond.

Claims 2 through 4 separately identify these attachment configurations. The claims do not require a particular spacer length or a single specific linker chemistry.

This limitation distinguishes the claimed molecules from:

Somatostatin analogs labeled at internal amino-acid residues;
Peptides labeled only through noncovalent association;
Peptides carrying a radiometal without a covalently attached chelator;
Non-somatostatin receptor ligands.

Somatostatin peptide requirement

The peptide must be a somatostatin peptide capable of targeting somatostatin receptors. The claim language is broad enough to encompass natural somatostatin-derived sequences and synthetic analogs, provided the peptide retains the claimed receptor-targeting function.

The claim does not expressly require:

A particular receptor subtype;
A specific binding affinity;
A minimum tumor-to-background ratio;
A particular dose;
A specific imaging time point; or
A specific diagnostic result.

Recording receptor localization

The final method step requires recording the localization of the receptors targeted by the peptide. This language supports imaging methods in which the distribution of the radiolabeled or otherwise detectable peptide is observed and recorded.

A product-only theory of infringement would not be sufficient. The asserted claim is a method claim, so infringement would generally require performance of the administration and localization steps, or inducement or contributory infringement theories tied to those steps.

What peptide structures are protected by claims 5 through 9?

Claims 5 through 9 narrow the broad method by defining a particular peptide framework and related substituent options.

Claim 5 covers a formula I peptide with specified residues and substituent classes. The defined structure includes combinations involving:

Phenylalanine or substituted phenylalanine;
Tryptophan, including D- or L-tryptophan;
Lysine or aminocyclohexylalanine/glycine analogs;
Threonine, serine, valine, phenylalanine, isobutyric acid, or butyric acid residues; and
Various C-terminal or side-chain substituents.

The claim permits multiple substitutions involving halogen, nitro, amino, hydroxy, alkyl, alkoxy, phenylalkyl, ester, amide, and related groups.

Claim 9 then narrows the invention to a specific peptide structure shown in the patent's formula 58, complexed with a detectable element. Because the supplied claim text does not reproduce that structure in machine-readable form, the exact sequence and stereochemical identity must be taken from the issued patent drawing and specification. The claim should not be treated as covering every somatostatin analog solely because it falls within the general receptor-targeting concept.

Stereochemistry

Claim 5 requires the B, D, and E residues to have the L-configuration. The C and G residues can independently have L- or D-configuration. This limitation matters for products using D-amino-acid substitutions, because a sequence that otherwise resembles the claimed analog may fall outside the claim if its stereochemistry differs from the expressly permitted configurations.

Which chelators and radionuclides fall within the claims?

Claims 6 through 8 identify a broad set of chelating groups.

Chelator classes in claim 6

The listed classes include:

Iminodicarboxylic groups;
Polyaminopolycarboxylic groups;
Macrocyclic amines;
Defined amino-acid-derived chelating structures;
Bis-aminothiol derivatives;
Dithiasemicarbazone derivatives;
Propylene amine oxime derivatives;
Diamide dimercaptides;
Porphyrins; and
Deferoxamine derivatives.

Named chelators in claims 7 and 8

The claims specifically identify:

Chelator	General significance
EDTA	Acyclic aminopolycarboxylate chelator
DTPA	Acyclic polyaminopolycarboxylate chelator
EGTA	Calcium-selective aminopolycarboxylate chelator
HBED	Hydroxybenzyl-substituted chelator
TTHA	Extended acyclic polyaminocarboxylate
DOTA	Macrocyclic tetraazacyclododecane chelator
TETA	Macrocyclic tetraazacyclotetradecane chelator
TITRA	Macrocyclic cyclotridecane-related chelator
TETRA	Macrocyclic tetraazacyclotetradecane derivative
HMPAO	Technetium-oriented oxime chelator

Claims 7 and 8 also cover substituted versions, including p-isothiocyanatophenyl alkyl derivatives. These substitutions are relevant because isothiocyanate groups can react with peptide amino groups to form thiourea linkages.

Indium-111 and yttrium-90

Claim 11 expressly identifies complexes using indium-111 or yttrium-90. Indium-111 is a gamma-emitting radionuclide used for SPECT-type imaging. Yttrium-90 is primarily a beta-emitting therapeutic radionuclide, not a conventional gamma or positron imaging isotope.

This creates an internal technical tension between claim 1's detectable-element categories and claim 11's express inclusion of yttrium-90. Claim 11 depends on claim 10, which depends on claim 9 and ultimately claim 1. A dependent claim cannot ordinarily eliminate an express limitation in the parent claim. The practical interpretation is that the patent contemplated both imaging and therapeutic radionuclide applications, but the enforceable scope of claim 11 would depend on claim construction and the precise disclosure and prosecution history.

What were the key U.S. patent dates and expiration dates?

Event	Date or status
U.S. patent	5,753,627
Patent title	Somatostatin receptor scintigraphy
Issue date	May 19, 1998
Patent term framework	Pre-1995 application rules, subject to the applicable statutory transition
U.S. expiration	2015, based on the 17-year term from issuance
Current enforceability	Expired
Current blocking effect	None for the expired claims

The patent's expiration removes the principal patent-based exclusivity associated with its broad receptor-targeted imaging method. Patent expiration does not remove later patents that claim narrower products or manufacturing techniques.

When did somatostatin receptor imaging products receive FDA approval?

The commercial products most closely associated with the claimed technology include the following:

Product	Active radiopharmaceutical	Company history	FDA milestone
OctreoScan	Indium In-111 pentetreotide	Mallinckrodt and predecessor organizations	FDA approval in 1994
Netspot	Gallium Ga-68 dotatate	Advanced Accelerator Applications, now part of Novartis	FDA approval in 2016
Lutathera	Lutetium Lu-177 dotatate	Advanced Accelerator Applications, now Novartis	FDA approval in 2018

OctreoScan is a diagnostic somatostatin-receptor imaging product using indium-111 pentetreotide. Netspot uses gallium-68 dotatate for PET imaging. Lutathera uses lutetium-177 dotatate for peptide receptor radionuclide therapy, or PRRT. FDA product approval records and labeling establish the approved indications, dosing, preparation requirements, and safety controls for these products. [2]-[4]

The products are technically related to the patent's general concept but are not automatically covered by every claim. Coverage depends on the exact peptide, linker, chelator, radionuclide, and method performed.

What is the Orange Book status of U.S. Patent 5,753,627?

U.S. Patent 5,753,627 is not a current source of Orange Book exclusivity for OctreoScan, Netspot, or Lutathera.

The Orange Book is product-specific. A patent must be properly listed against an approved drug product to create the statutory notice and Paragraph IV framework associated with an abbreviated new drug application. A broad, expired method patent does not independently prevent approval of a generic or follow-on product.

The relevant regulatory implications are:

An expired patent cannot support a current Paragraph IV enforcement action.
A patent not listed for the reference product does not create an Orange Book certification obligation.
Orange Book listing does not determine the full patent position for drug-device combinations, manufacturing methods, or unlisted formulation rights.
Radiopharmaceutical competitors may face regulatory, facility, isotope-supply, and quality-control barriers even when no blocking patent remains.

The current Orange Book should be reviewed for product-specific listings, expiration dates, and any patent delistings. [5]

Are there Paragraph IV challenges involving this patent?

No current Paragraph IV risk arises from U.S. Patent 5,753,627 because the patent expired in 2015.

Paragraph IV litigation could still arise from later patents covering:

Dotatate or other specific somatostatin analogs;
Lutetium-177, gallium-68, or other radionuclide complexes;
Drug-product formulations;
Kit components and reconstitution procedures;
Dosage regimens;
Treatment of specific neuroendocrine tumor populations;
Radiolabeling and purification processes; and
Combination treatment with amino-acid infusions or other renal-protective protocols.

For radiopharmaceuticals, the relevant commercial challenge may involve a 505(b)(2) application, an abbreviated pathway, a new drug application, or a product-specific regulatory strategy rather than a conventional small-molecule ANDA.

What patent litigation and settlement issues affect the patent?

The supplied claim set and the patent's expired status do not identify an active litigation or settlement dispute involving this patent.

Because the patent expired before the current commercial expansion of Netspot and Lutathera, its principal commercial effect was historical. Any relevant disputes involving modern somatostatin receptor products are more likely to concern later patents, regulatory exclusivity, licensing rights, or product-specific intellectual property.

The absence of a current enforceable term also means that a company cannot use this patent alone to obtain:

An injunction against a competing radiolabeled somatostatin peptide;
A damages claim for post-expiration activities;
A current Paragraph IV settlement; or
A post-expiration royalty obligation unless a separate contract applies.

How does this patent compare with later somatostatin receptor patents?

The patent is broad at the method level and relatively open-ended at the chelator level. Later patent estates generally pursue narrower but commercially more valuable rights.

Patent layer	Typical claim focus	Relevance after expiration of U.S. 5,753,627
Foundational method	Somatostatin peptide, N-terminal chelator, detectable metal, receptor localization	No current blocking effect
Specific peptide	DOTATATE, DOTATOC, or related analog sequence	May create product-specific barriers
Specific radionuclide complex	Lu-177, Ga-68, Cu-64, Y-90, or other metal-peptide complex	May affect diagnostic or therapeutic products
Formulation	Kit, buffer, stabilizer, excipient, pH, reconstitution	Can delay or narrow generic entry
Manufacturing	Radiolabeling, purification, precursor production, sterility controls	May create process barriers
Method of treatment	PRRT dosing, patient selection, tumor indication, combination therapy	May support method-of-use enforcement
Device and kit	Vial configuration, shielding, generator, automated synthesis	May create separate commercial rights

The expired patent is strongest as prior art and historical platform IP. It is no longer strong as exclusionary rights. A modern freedom-to-operate analysis should focus on claims that require the exact marketed peptide and radionuclide combination.

How strong is the patent estate for somatostatin receptor radiopharmaceuticals?

The historical estate was strong in conceptual breadth but weaker as a current commercial asset because its term ended before the largest U.S. market expansion for peptide receptor radionuclide therapy.

Strengths

Broad coverage of N-terminal chelator attachment;
Coverage of direct and indirect linkages;
Multiple chelator classes;
Multiple detectable-element categories;
Coverage of both imaging and, at least in part, radionuclide therapy concepts;
Specific identification of EDTA, DTPA, DOTA, TETA, and related chelators;
Claims directed to tumor and metastasis localization rather than only laboratory binding assays.

Limitations

The patent is expired;
Claim 1 requires the N-terminal attachment architecture;
Claims 5 through 9 contain complex structural and stereochemical limitations;
The specification and prosecution history may limit interpretation of broad Markush language;
Claim 11's inclusion of yttrium-90 creates a parent-claim dependency issue;
Later products may use different sequences, linkers, labeling conditions, or formulations;
The claims do not directly cover every somatostatin-receptor ligand or every radiopharmaceutical product.

The patent has substantial historical significance for the technology class but no current standalone exclusionary strength in the United States.

What generic entry risks exist for OctreoScan, Netspot, and Lutathera?

OctreoScan

OctreoScan is the product most closely aligned with the patent's indium-111 imaging concept. The expired patent does not block competing indium-111 somatostatin-receptor imaging products. Remaining barriers may include:

Reference-product regulatory requirements;
Radiochemical manufacturing controls;
Sterility and quality systems;
Availability of indium-111;
Kit validation and shelf-life data;
Product-specific patents, if any remain listed or enforceable.

Netspot

Netspot uses gallium-68 dotatate, a PET radiopharmaceutical. Its commercial protection is more likely to involve later patents and regulatory exclusivity tied to the specific peptide, kit, precursor, formulation, generator or cyclotron process, and manufacturing workflow. U.S. Patent 5,753,627 does not block gallium-68 products after 2015.

Lutathera

Lutathera uses lutetium-177 dotatate for PRRT. The expired patent does not prevent competing lutetium-177 somatostatin analogs. The more important barriers are likely to include:

Product-specific composition claims;
Radiolabeling and purification processes;
Dosage and administration protocols;
Patient-selection and treatment-method claims;
Commercial-scale radionuclide supply;
GMP production and radiation-handling infrastructure;
FDA approval requirements for therapeutic radiopharmaceuticals.

Lutathera received FDA approval through the new drug application pathway, and its regulatory protection cannot be inferred from the expiration of the earlier patent. [4]

Does biosimilar risk apply to this patent?

No. Biosimilar law does not apply to U.S. Patent 5,753,627 because the patent concerns peptide radiopharmaceutical methods, not a biological product subject to the Biologics Price Competition and Innovation Act.

Competitive products would generally be characterized as:

Generic or follow-on radiopharmaceuticals;
505(b)(2) products;
New drug applications;
Compounded or institutionally prepared radiopharmaceuticals, where legally permissible; or
New molecular or radiometal-peptide products.

A follow-on product may avoid the patent entirely by using a different peptide, chelator, radionuclide, linker, or administration method.

What licensing and geographic coverage issues matter?

The patent provided U.S. rights only through the U.S. patent system. Corresponding foreign family members may have had different filing dates, prosecution outcomes, claim scopes, and expiration dates. The U.S. expiration does not establish the status of European, Japanese, Swiss, or other national rights.

For commercial diligence, the relevant geographic questions are:

Whether a foreign counterpart remains enforceable;
Whether local supplementary protection or patent-term extension applied;
Whether a product patent is held by a different entity from the platform patent;
Whether the radionuclide precursor is licensed separately;
Whether manufacturing rights are divided among the peptide, chelator, kit, and radiolabeling suppliers.

No current licensing obligation can be attributed to the expired U.S. patent from the claim text alone. The commercial structure of modern products may include licenses involving peptide sequences, radiolabeling technology, isotope supply, manufacturing facilities, or university-originated inventions.

What manufacturing and intellectual-property barriers remain after expiration?

Patent expiration removes one legal barrier but does not eliminate operational barriers. Radiopharmaceutical competition remains dependent on:

GMP peptide synthesis;
Chelator conjugation and characterization;
Radionuclide availability;
Radiolabeling yield and reproducibility;
Sterile filtration and aseptic filling;
Short product shelf life;
Radiation-shielded production;
Validated transport and distribution;
Dosimetry and radiation-safety programs;
Batch-release testing;
Stability data;
Hospital nuclear-pharmacy infrastructure.

These barriers can support commercial differentiation even when platform patent claims are expired. Trade secrets and know-how may remain enforceable indefinitely if properly maintained, but they do not extend the term of the patent.

What is the commercial exposure from the patent's expiration?

The expiration of U.S. Patent 5,753,627 increases long-term competitive freedom for:

Indium-111 somatostatin-receptor imaging;
Gallium-68 somatostatin-receptor PET agents;
Lutetium-177 peptide receptor radionuclide therapy;
Yttrium-90 somatostatin-receptor therapy;
DOTA-, DTPA-, EDTA-, and related chelator conjugates;
Alternative somatostatin analog sequences.

The largest commercial exposure is not direct royalty loss under the expired patent. It is erosion of platform differentiation. Competitors can design products around later patents while using the basic receptor-targeted imaging concept without infringing this patent.

Key Takeaways

U.S. Patent 5,753,627 claims in vivo localization of somatostatin-receptor-positive tumors using N-terminal chelator-linked somatostatin peptides.
Claim 1 is broad and covers gamma-emitting, positron-emitting, fluorescent-metal, and paramagnetic detection systems.
Claims 5 through 9 narrow the invention to defined peptide structures, stereochemistry, and substituent classes.
Claims 6 through 8 cover extensive chelator categories, including DOTA, DTPA, EDTA, TETA, TITRA, TETRA, and HMPAO derivatives.
Claim 11 expressly identifies indium-111 and yttrium-90, although the yttrium-90 limitation raises a dependency and detectability issue.
The patent issued May 19, 1998, and expired in 2015.
It is not a current U.S. blocking patent for OctreoScan, Netspot, Lutathera, or competing products.
Current freedom-to-operate risk is more likely to arise from later composition, formulation, manufacturing, dosing, and method-of-treatment patents.
Biosimilar analysis is not applicable.
FDA approval, isotope supply, GMP production, and nuclear-pharmacy infrastructure remain material barriers after patent expiration.

FAQs About U.S. Patent 5,753,627

Is U.S. Patent 5,753,627 still enforceable?

No. The U.S. patent term expired in 2015, so the patent cannot currently block commercial activity in the United States.

Does the patent cover Lutathera?

The patent covers the general concept of detecting or localizing somatostatin-receptor-targeted peptide complexes, but it does not provide a current blocking right against Lutathera. Lutathera's exact peptide, radionuclide, formulation, and treatment claims must be analyzed under later patents.

Does the patent cover gallium-68 dotatate PET imaging?

The broad claim language can reach certain positron-emitting somatostatin peptide complexes, including potentially gallium-68 products if all claim limitations are met. The patent is expired and therefore does not currently block gallium-68 dotatate commercialization.

Can a competitor use DOTA-linked somatostatin peptides without a license?

Yes, the expired U.S. patent does not require a current license. A competitor must still evaluate later patents covering the specific peptide sequence, radionuclide, linker, formulation, manufacturing process, or treatment regimen.

Is this patent relevant to European market entry?

Only as a historical or prior-art reference unless a separate foreign family member remained enforceable. U.S. expiration does not establish the legal status of corresponding patents in Europe or other jurisdictions.

References

United States Patent and Trademark Office. (1998). Somatostatin receptor scintigraphy (U.S. Patent No. 5,753,627).
U.S. Food and Drug Administration. (1994). OctreoScan prescribing information.
U.S. Food and Drug Administration. (2016). Netspot prescribing information.
U.S. Food and Drug Administration. (2018). Lutathera prescribing information.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	403476	⤷ Start Trial
Austria	A901789	⤷ Start Trial
Australia	4587189	⤷ Start Trial
Australia	633859	⤷ Start Trial
Belgium	1002296	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 5,753,627